References

  1. Rossaint R, Falke KJ, López F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328(6):399-405.

  2. Gerlach H, Rossaint R, Pappert D, Falke KJ. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest. 1993;23(8):499-502.

  3. Abman SH, Griebel JL, Parker DK, Schmidt JM, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr. 1994;124(6):881-888.

  4. INOMAX [package insert]. Hazelwood, MO: Mallinckrodt Pharmaceuticals; 2015.

  5. Puthiyachirakkal M, Mhanna MJ. Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review. Front Pediatr. 2013;1(23):1-6.

  6. Keszler M, Abubakar KM. Respiratory System. In: Elzouki AY, Harfi HA, Nazer HM, et al, eds. Textbook of Clinical Pediatrics. 2nd ed. New York, NY: Springer-Verlag Berlin Heidelberg; 2012:195-216.

  7. Clark RH, Kueser TJ, Walker MW, et al. Clinical Inhaled Nitric Oxide Research Group (CINRGI). Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000;342(7):469-474.

  8. Data on file. Hampton, NJ: Mallinckrodt Pharmaceuticals; 2013.

  9. Golombek SG, Young JN. Efficacy of inhaled nitric oxide for hypoxic respiratory failure in term and late preterm infants by baseline severity of illness: a pooled analysis of three clinical trials. Clin Ther. 2010;32(5):939-948.

  10. Konduri GG, Sokol GM, Van Meurs KP, et al. Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term/late preterm neonates with moderate hypoxic respiratory failure. J Perinatol. 2013;33(12):944-949.

  11. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med. 1997;336(9):597-604.

  12. Williams LJ, Shaffer TH, Greenspan JS. Inhaled nitric oxide therapy in the near-term or term neonate with hypoxic respiratory failure. Neonatal Netw. 2004;23(1):5-13.

  13. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg. 1996;62(6):1759-1764.

  14. Lavoie A, Hall JB, Olson DM, Wylam ME. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med. 1996;153(6 pt 1):1985-1987.

  15. The Joint Commission. The Joint Commission announces 2014 National Patient Safety Goal. http://www.jointcommission.org/assets/1/18/JCP0713_Announce_New_NSPG.pdf. Published July 2013. Accessed December 4, 2015.

  16. INOmax DSIR Plus Operation Manual. Hampton, NJ: INO Therapeutics LLC; 2014.

  17. INOmax DSIR Plus MRI Operation Manual. Hampton, NJ: INO Therapeutics LLC; 2015.

  18. INOmax DSIR Operation Manual. Hampton, NJ: INO Therapeutics LLC; 2012.

  19. US Food and Drug Administration. Guidance document for premarket notification submissions for nitric oxide delivery apparatus, nitric oxide analyzer and nitrogen dioxide analyzer. http://www.fda.gov/downloads/MedicalDevices/…/ucm073767.pdf. Published January 24, 2000. Accessed October 30, 2015.

  20. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. Pediatrics. 1998;101(3 pt 1):325-334.

  21. Konduri GG, Solimano A, Sokol GM, et al; Neonatal Inhaled Nitric Oxide Study Group. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure. Pediatrics. 2004;113(3 pt 1):559-564.